Search Results
Your search for The A matches 31871 pages
Showing 1901 - 1950Bispecific T-Cell Engager Tarlatamab in Previously Treated Patients With Small Cell Lung Cancer
In the phase II DeLLphi-301 trial—presented at the European Society for Medical Oncology (ESMO) Congress 2023 (Abstract LBA92) and reported by Ahn et al in The New England Journal of Medicine—tarlatamab, a bispecific T-cell engager targeting delta-like ligand 3 and CD3, exhibited activity in...
2023 National Youth Tobacco Survey Shows Drop in E-Cigarette Use Among High School Students
On November 2, the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) released data from the 2023 National Youth Tobacco Survey (NYTS) on tobacco product use among U.S. youth. The findings—which were collected between March and June 2023 and were...
Perioperative Durvalumab in Resectable NSCLC: AEGEAN Trial
As reported in The New England Journal of Medicine by John V. Heymach, MD, PhD, and colleagues, the phase III AEGEAN trial has shown that perioperative durvalumab improved event-free survival and pathologic complete response (pCR) rate in patients with resectable non–small cell lung cancer ...
Novel Blood Test May Offer Early Cancer Detection
Researchers have developed a highly sensitive blood test capable of early detection by identifying a key protein produced by cancer cells, according to a novel study published by Taylor et al in Cancer Discovery. Background Many tumors become deadly by remaining asymptomatic until they’re too...
Immune Checkpoint Inhibition With Single-Fraction Stereotactic Radiosurgery May Not Increase Risk of Radiation Necrosis in Patients With NSCLC Brain Metastases
Researchers have explored the impact of immune checkpoint inhibition and single-fraction stereotactic radiosurgery on radiation necrosis in patients with non–small cell lung cancer (NSCLC) brain metastases, according to a novel study published by Lehrer et al in the Journal of Neuro-Oncology. Study ...
Addition of First-Line Pembrolizumab to Chemotherapy in HER2-Negative Advanced Gastric Cancer
As reported in The Lancet Oncology by Sun Young Rha, MD, and colleagues, the phase III KEYNOTE-859 trial has shown that the addition of first-line pembrolizumab to chemotherapy was associated with a statistically significant improvement in overall survival in patients with HER2-negative advanced...
International Group of Surgical Oncologists Presents New Commission Outlining Pragmatic Solutions to Improve Cancer Surgery Outcomes Worldwide
Building upon recommendations from the 2015 Lancet Oncology Global Cancer Surgery Commission, a new Commission report aims to provide a pragmatic roadmap for decision-makers to reduce inequities and promote safe, timely, and affordable cancer surgery for every patient. The Commission report was...
ACS Releases Updated Lung Cancer Screening Guideline
Lung cancer incidence overall has been declining in the United States since 1992 and since 2006–2007 for both men and women by 2.7% annually and 1.1%, respectively, and overall mortality rates have declined in both men and women due to smoking cessation efforts and advances in therapy and early...
Advanced RET-Mutant Medullary Thyroid Cancer: First-Line Selpercatinib
As presented at the European Society for Medical Oncology (ESMO) Congress 2023 (Abstract LBA3) and reported in The New England Journal of Medicine by Hadoux et al, an interim analysis from the phase III LIBRETTO-531 trial has shown improved progression-free survival with selpercatinib vs...
3-Year Overall Survival With Tebentafusp in Previously Untreated Advanced Uveal Melanoma
In an analysis presented at the European Society for Medical Oncology (ESMO) Congress 2023 (Abstract LBA50) and reported in The New England Journal of Medicine by Jessica C. Hassel, MD, and colleagues, overall survival at 3 years in the phase III IMCgp100-202 trial continued to favor...
FDA Approves Pembrolizumab Plus Chemotherapy for Biliary Tract Cancer
On October 31, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) to be used with gemcitabine and cisplatin for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. KEYNOTE-966 Efficacy was evaluated in KEYNOTE-966...
Insurance Coverage Disruptions May Reduce Rate of Cancer Screenings
Investigators have found that U.S. adult patients with prior insurance coverage disruptions may be less likely to receive guideline-concordant and past-year cancer screenings compared with those with continuous coverage, according to new findings presented by Shi et al at the 2023 ASCO Quality Care ...
Expanded Soy Production in Brazil May Be Linked to Increased Mortality Among Pediatric Patients With ALL
Researchers have reported that soy expansion and the subsequent increase of pesticide use in Brazil’s Cerrado and Amazon biomes may correlate with an increased risk of mortality among pediatric patients with acute lymphoblastic leukemia (ALL). The study was published by Skidmore et al in...
Ze-rui Zhao, PhD, on Resectable NSCLC: SBRT With Sequential Immunochemotherapy
Ze-rui Zhao, PhD, of China’s Sun Yat-sen University Cancer Center, discusses new phase II findings on stereotactic body radiation therapy (SBRT) with sequential immunochemotherapy as a neoadjuvant treatment of patients with resectable non–small cell lung cancer (NSCLC). This therapy yielded a high...
Association of Germline EGFR Mutations With Familial Lung Cancer
In the INHERIT study—reported in the Journal of Clinical Oncology—Geoffrey R. Oxnard, MD, FASCO, and colleagues identified associations between germline EGFR mutations and familial lung cancer. As stated by the investigators, “The genomic underpinnings of inherited lung cancer risk are poorly...
Patients With Newly Diagnosed NSCLC or Melanoma May Receive Limited Documentation of Treatment Cost Discussions
Investigators have uncovered that only about 25% of patients newly diagnosed with advanced cancer have documented physician discussions about the costs of care, which may make it more difficult to identify patient needs and track the outcomes of referrals for assistance, according to new findings...
Nivolumab With or Without Nivolumab/Ipilimumab Boost in Metastatic Renal Cell Carcinoma
In the phase II TITAN-RCC trial reported in The Lancet Oncology, Grimm et al found that a strategy of nivolumab monotherapy with or without nivolumab/ipilimumab as an immunotherapeutic boost was associated with activity in patients with metastatic clear cell renal cell carcinoma. Study Details In...
Role of Crowdfunding Campaigns in Covering Medical Expenses for Cancer Survivors
Investigators have discovered that cancer survivors in the United States may be increasingly utilizing crowdfunding campaigns like GoFundMe to help cover the costs of medical and other basic household expenses, according to new findings presented by Zheng et al and Yu et al at the 2023 ASCO Quality ...
Sotorasib Plus Panitumumab in KRAS G12C–Mutated Advanced Colorectal Cancer: CodeBreaK 300
The phase III CodeBreaK 300 trial showed that sotorasib plus panitumumab improved progression-free survival vs standard care in patients with KRAS G12C–mutated refractory metastatic colorectal cancer. Findings were presented at the European Society for Medical Oncology (ESMO) Congress 2023 (LBA10)...
Cardiovascular Disease and Cancer: A Reciprocal Relationship?
More attention is being paid to the topic of cardio-oncology, where the focus is on patients with cancer who may be at risk for developing cardiovascular diseases as a result of anticancer treatments. However, a less well-known but related clinical area is now garnering some interest. Referred to...
Expert Point of View: Rohann J.M. Correa, MD, PhD
Abstract discussant Rohann J.M. Correa, MD, PhD, a radiation oncologist at London Health Sciences Centre and Assistant Professor at Western University, Canada, shared his insights on this landmark clinical trial for the treatment of kidney cancers. “FASTRACK II represents an important milestone,...
Stereotactic Body Radiation Therapy Demonstrates ‘Exceptional Control’ in Primary Renal Cell Carcinoma
Although surgery remains the standard of care for primary renal cell carcinoma, a novel, noninvasive approach has yielded positive results that could pave the way for future treatment strategies, according to data presented at the 2023 American Society for Radiation Oncology (ASTRO) Annual...
Expert Point of View: Neha Vapiwala, MD, FASTRO
Discussant of the PACE-B abstract, Neha Vapiwala, MD, FASTRO, acknowledged the impressive efforts of PACE investigators to elucidate the various treatment options for patients with localized prostate cancer—a challenging task because of the frequent absence of clear evidence. Dr. Vapiwala is...
PACE Trials Support Stereotactic Body Radiotherapy for Some Patients With Localized Prostate Cancer
Prostate cancer treatment just got a major boost from the PACE trials, which may have established a new standard of care in low- and favorable intermediate-risk disease, according to data presented at the 2023 American Society for Radiation Oncology (ASTRO) Annual Meeting.1 The results of the phase ...
Intraductal Papillary Mucinous Neoplasms: Risk of Pancreatic Cancer
In a retrospective cohort study reported in JAMA Network Open, de la Fuente et al found that the risk of pancreatic cancer in patients with Fukuoka criteria–negative intraductal papillary mucinous neoplasms (F-N IPMNs) did not differ from that in patients without IPMNs. In addition, the small...
Expert Point of View: Marina C. Garassino, MD
“CheckMate 77T shows very promising results to support the use of perioperative nivolumab in resectable NSCLC,” said formal discussant Marina C. Garassino, MD, of the University of Chicago. “In particular, the trial demonstrated that patients could achieve incredible disease control rates. These...
Perioperative Nivolumab Plus Chemotherapy Improves Event-Free Survival in Resectable Non–Small Cell Lung Cancer
A perioperative regimen of neoadjuvant nivolumab plus chemotherapy followed by surgery and adjuvant nivolumab achieved a statistically significant and clinically meaningful improvement in event-free survival compared with neoadjuvant chemotherapy plus placebo followed by surgery and adjuvant...
FDA Approves Toripalimab-tpzi for Nasopharyngeal Carcinoma
On October 27, the U.S. Food and Drug Administration (FDA) approved toripalimab-tpzi (Loqtorz) with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma. The FDA also approved toripalimab-tpzi as a single agent for...
Two New Studies Using CancerLinQ Data
Two new studies—presented by Drumheller et al and Vento et al at the 2023 ASCO Quality Care Symposium—utilized data from ASCO’s CancerLinQ® database (Abstracts 418 and 532). One study revealed deficiencies in biomarker testing and tracking in electronic health records, and the other analyzed...
Datopotamab Deruxtecan May Improve Progression-Free Survival in Patients With Metastatic NSCLC
The TROP-2–directed antibody-drug conjugate datopotamab deruxtecan may significantly improve progression-free survival in patients with metastatic non–small cell lung cancer (NSCLC), especially in patients with non–squamous cell tumors, according to new findings simultaneously published by Ahn et...
Sequential CD19- and CD22-Directed CAR T-Cell Therapy in Pediatric B-Cell ALL
In a Chinese single-center phase II study reported in The Lancet Oncology, Pan et al found that sequential CD19- and CD22-directed chimeric antigen receptor (CAR) T-cell therapy was active in pediatric patients with refractory or relapsed B-cell acute lymphocytic leukemia (ALL). Study Details In...
Enzalutamide With or Without Leuprolide and Leuprolide Alone in Biochemically Recurrent Prostate Cancer
In the phase III EMBARK trial reported in The New England Journal of Medicine, Stephen J. Freedland, MD, and colleagues found that enzalutamide/leuprolide and enzalutamide alone improved metastasis-free survival vs leuprolide alone in patients with high-risk biochemical recurrence of prostate...
Pembrolizumab Plus Lenvatinib as Second- and Third-Line Treatments of Pleural Mesothelioma
In a Dutch single-institution phase II trial (PEMMELA) reported in The Lancet Oncology, Douma et al found that the combination of pembrolizumab and lenvatinib showed activity as second- and third-line treatments of patients with pleural mesothelioma. Study Details A total of 38 evaluable patients...
ASCO Launches ‘ASCO Certified’ to Ensure the Delivery of High-Quality, Patient-Centered Cancer Care to Every Patient
On October 25, 2023, ASCO announced the launch of its new flagship quality program ASCO Certified™, with the goal of ensuring that every patient with cancer has access to high-quality, patient-centered, coordinated cancer care.1 The program, which officially launched on October 27, 2023, to...
PFAS Exposure May Increase Risk of Thyroid Cancer
Researchers may have discovered a link between certain per- and polyfluoroalkyl substances (PFAS)—also referred to as "forever chemicals"—and an increased risk of thyroid cancer, according to a recent study published by van Gerwen et al in eBioMedicine. Background PFAS are a large, complex group of ...
Early Triple-Negative Breast Cancer
This is Part 3 of Updates in Early-Stage Breast Cancer,, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Erika Hamilton, Michael Danso, and Komal Jhaveri discuss the management of early triple-negative breast cancer. The...
Early Node-Negative HER2-Positive Breast Cancer
This is Part 2 of Updates in Early-Stage Breast Cancer,, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Erika Hamilton, Michael Danso, and Komal Jhaveri discuss the management of early node-negative HER2-positive breast...
Early Hormone Receptor–Positive/HER2-Negative Breast Cancer
This is Part 1 of Updates in Early-Stage Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Erika Hamilton, Michael Danso, and Komal Jhaveri discuss the management of early hormone receptor–positive/HER2-negative...
Text Message–Based Prescreening Could Benefit Patients Receiving Immunotherapy
Researchers have found that a text message–based program in combination with routine laboratory testing could safely accelerate patients to treatment with immune checkpoint inhibitors, eliminate the need for in-person assessments with their physicians, and save them about 1.5 hours in total wait...
Yoga-Based Supportive Care May Prevent Treatment-Related Complications in Patients With Head and Neck Cancer
Yoga-based supportive care may help alleviate the negative side effects of radiation treatment, decrease the use of feeding tube placements, and reduce emergency department visits in patients with head and neck cancer, especially when family caregivers participate, according to new findings...
Mind-Body Fitness Classes May Reduce Unplanned Hospitalizations, Urgent Care Visits During Cancer Care
Participation in virtual mind-body fitness classes may be effective at reducing hospitalizations, urgent care visits, and the length of hospital stays among patients with cancer by about 50%, according to new findings presented by Mao et al at the 2023 ASCO Quality Care Symposium (Abstract 473)....
Perioperative Chemotherapy and Pembrolizumab in Locally Advanced Resectable Gastric and Gastroesophageal Junction Adenocarcinomas
In a phase II trial reported in JAMA Oncology, Manji et al found that perioperative chemotherapy and pembrolizumab showed activity in locally advanced resectable gastric and gastroesophageal junction adenocarcinoma. Study Details Thirty-four evaluable patients were enrolled in the...
Primary Care Intervention to Improve Follow-up of Overdue Abnormal Cancer Screening Test Results
In a study reported in JAMA, Atlas et al found that a primary care intervention including electronic health record (EHR) reminders and patient outreach with or without patient navigation improved timeliness of follow-up of overdue abnormal cancer screening test results. Study Details The open-label ...
FDA Approves Ivosidenib for Myelodysplastic Syndromes
On October 24, the U.S. Food and Drug Administration (FDA) approved ivosidenib (Tibsovo) for adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation, as detected by an FDA-approved test. The FDA also approved the...
CMS, Congress Must Work Together to Support Access to Cancer Care and Physician Practice Health
In letters to the Centers for Medicare & Medicaid Services (CMS), the Association for Clinical Oncology (ASCO) commented on provisions that impact cancer care for Medicare beneficiaries in the 2024 Medicare Physician Fee Schedule (MPFS) and Quality Payment Program (QPP) proposed rule, as well...
ASCO Response to Drug Shortages Request for Information
The Association for Clinical Oncology (ASCO) responded to a bicameral Request for Information (RFI) on the underlying factors driving drug shortages. The Association’s comments highlighted the impact of the shortages on patient care and pointed to economic failures and supply chain vulnerabilities...
Overcoming the Challenges of Treating Adolescents and Young Adults With Cancer Living in Rural Communities
It is widely acknowledged that patients with cancer living in rural areas of the United States face limited access to medical and oncology providers, often have to travel long distances to receive care, and experience obstacles in clinical trial participation—all of which affect quality of care and ...
Annual Report to the Nation on COVID-19’s Impact on Cancer Diagnosis Finds Sharp Declines in New Diagnoses of Six Major Cancers
Findings from the Annual Report to theNation on the Status of Cancer, Part 2: Early Assessment of the COVID-19 Pandemic’s Impact on Cancer Diagnosis show new diagnoses of six major cancer types in the United States fell sharply between March and May 2020, coinciding with the beginning of the...
Diagnosis of Cardiovascular Disease and Risk of Subsequent Incident Cancer Diagnosis
In a retrospective cohort study reported in JACC: CardioOncology, Caitlin F. Bell, MD, of the Division of Cardiovascular Medicine, Stanford University School of Medicine, and colleagues found that persons with a diagnosis of cardiovascular disease (CVD) were more likely to have a subsequent...
Expert Point of View: Matthew Hatton, MBChB, MSc, FRCP, FRCR and Charles Simone, MD
Invited discussant Matthew Hatton, MBChB, MSc, FRCP, FRCR, a consultant and Honorary Professor in Clinical Oncology at Weston Park Cancer Center, Sheffield, UK, pointed out that the original analysis of RTOG 0617 was disappointing and failed to find evidence that intensity-modulated radiation...
